Pharma

By Laura Lovett May 21, 2019
This morning, artificial-intelligence-enabled monitoring and decision support platform Biofourmis announced a $35 million Series B raise. The round was led by Sequoia India and MassMutual Ventures with participation from EDBI, Jianke and existing investors Openspace Ventures, Aviva Ventures and SGInnovate.  The funding announcement coincided with the news that the Singaporean company will be...
By Dave Muoio May 21, 2019
This morning Verily announced a series of new strategic partnerships with four global pharmaceutical companies that will bring low-burden digital data collection and analysis tools to clinical research projects. Alongside Novartis, Otsuka, Pfizer and Sanofi, the Alphabet subsidiary will employ its Project Baseline platform to increase the number and diversity of study populations by making it...
By Dave Muoio May 16, 2019
Express Scripts will be releasing a stand-alone formulary in 2020 that highlights vetted digital health tools for the pharmacy benefit management firm’s payer and consumer customers, according to an announcement released this morning. The company said that it will be treating the new formulary in much the same way it would a similar resource for traditional medications. To be included, a digital...
By Joe Slavinsky May 16, 2019
About the author: Joe Slavinsky leads business development efforts with pharmaceutical, biotechnology and medical technology companies in his VP position at Propeller Health. A former epidemiologist, he worked at a hedge fund (Citadel) and an investment bank (Thomas Weisel Partners) as an equity research analyst covering small/mid-cap biotechnology companies. Joe joined Propeller from Gilead...
By Jonah Comstock May 9, 2019
Working with pharma giant Eli Lilly and Company, chronic disease management company Livongo has completed a retrospective analysis of more than 10,000 paitents, which suggests that Livongo's diabetes program can prevent $88 worth of medical spending per person per month.  Citing an average cost to employers of $68 per person per month, including about $30 worth of diabetes management products,...
By Dave Muoio May 6, 2019
Editor's Note: An original headline for this story contained an error, and has since been corrected. Boston- and San Francisco-based Pear Therapeutics, maker of prescription digital therapeutics for substance abuse, has kicked off a feasibility study for Pear-006, an in-development treatment for depressive symptoms in those with multiple sclerosis (MS). Pear Therapeutics has been developing Pear-...
By Laura Lovett April 30, 2019
Medisafe, a digital medication adherence app, is joining forces with Amerisource Bergen’s Lash Group in order to integrate the former’s management app into the latter’s hub services. The partnership seeks to help patients manage their medications and identify patients who need extra support.  As part of the deal Lash patients will be able to enroll in the Medisafe platform when  medication is...

23andMe kits at a Beverly Hills event in 2017. Credit: Matt Winkelmeyer, Getty Images

By Laura Lovett April 29, 2019
This morning 23andMe announced that it is teaming up with The Michael J. Fox Foundation for Parkinson’s Research on a new data and analytics platform dedicated to Parkinson’s research.  The new tool, dubbed Fox Insight Data Exploration Network (Fox DEN) is set to include patient surveys, de-identified genetic data and data exploration tools all aimed studying Parkinson’s.  Users who opt into the...
By Jonah Comstock April 25, 2019
Diplomat Pharmacy has released some data about its partnership with smart pill bottle maker AdhereTech as the companies also announced plans to expand that deal. The data, representative of more than 1,000 patients, shows that on average, patients who used the technology filled their medication one additional time over the course of the year. Patient retention was 12% higher, and the average...
By Dave Muoio April 9, 2019
Although still in its earliest chapters, the story of digital thherapeutics is beginning to pick up steam. Just six months ago, that the first software-only therapeutic cleared by the FDA, Pear Therapeutics’ reSET, kicked off a commercial launch driven by the sales channels expertise of an established pharmaceutical partner. Proteus, meanwhile, recently expanded dealings with its long-time pharma...
http://steroid-pharm.com

таблетки для потенции мужчин в аптеках

виагра или сиалис